ALUR: a phase 3 study of alectinib versus chemotherapy in previously treated ALK+ non-small cell lung cancer (NSCLC)

Annals of Oncology ◽

10.1093/annonc/mdw383.90 ◽

2016 ◽

Vol 27 ◽

pp. vi449 ◽

Author(s):

J. Wolf ◽

I.-J. Oh ◽

J. Mazieres ◽

J. de Castro ◽

C. Revil ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell Lung ◽

Phase 3 ◽

Previously Treated

Download Full-text

Phase 3 trial comparing nab-paclitaxel with docetaxel for previously treated advanced non–small cell lung cancer

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2021.03.027 ◽

2021 ◽

Author(s):

Yasuto Yoneshima ◽

Satoshi Morita ◽

Masahiko Ando ◽

Atsushi Nakamura ◽

Shunichiro Iwasawa ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell Lung ◽

Phase 3 ◽

Previously Treated

Download Full-text

Abstract CT114: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer (NSCLC): results of the phase 3 CheckMate 078 study

10.1158/1538-7445.am2018-ct114 ◽

2018 ◽

Author(s):

Yi-Long Wu ◽

Shun Lu ◽

Ying Cheng ◽

Caicun Zhou ◽

Jie Wang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Patient Population ◽

Chinese Patient ◽

Small Cell Lung ◽

Phase 3 ◽

Previously Treated

Download Full-text

Treatment Rationale and Design for J-AXEL: A Randomized Phase 3 Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

Clinical Lung Cancer ◽

10.1016/j.cllc.2016.08.003 ◽

2017 ◽

Vol 18 (1) ◽

pp. 100-103 ◽

Author(s):

Yasuto Yoneshima ◽

Satoshi Morita ◽

Masahiko Ando ◽

Satoru Miura ◽

Hiroshige Yoshioka ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell Lung ◽

Phase 3 ◽

Previously Treated

Download Full-text

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

The Lancet Oncology ◽

10.1016/s1470-2045(13)70355-3 ◽

2013 ◽

Vol 14 (10) ◽

pp. 953-961 ◽

Author(s):

Yuankai Shi ◽

Li Zhang ◽

Xiaoqing Liu ◽

Caicun Zhou ◽

Li Zhang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell Lung ◽

Phase 3 ◽

Double Blind ◽

Previously Treated

Download Full-text

Abstract CT041: ORIENT-3: A randomized, open-label, phase 3 study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small-cell lung cancer (sqNSCLC)

10.1158/1538-7445.am2021-ct041 ◽

2021 ◽

Author(s):

Yuankai Shi ◽

Lin Wu ◽

Xinmin Yu ◽

Yan Wang ◽

Puyuan Xing ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell Lung ◽

Phase 3 ◽

Open Label Phase ◽

Previously Treated

Download Full-text

Abstract CT289: Pembrolizumab plus lenvatinib vs docetaxel in patients with previously treated metastatic non-small-cell lung cancer (NSCLC) and PD after platinum-doublet chemotherapy and immunotherapy: Phase 3, randomized, open-label LEAP-008 trial

10.1158/1538-7445.am2020-ct289 ◽

2020 ◽

Author(s):

Natasha B. Leighl ◽

Rina Hui ◽

Delvys Rodríguez-Abreu ◽

Makoto Nishio ◽

Matthew D. Hellmann ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell Lung ◽

Phase 3 ◽

Previously Treated ◽

Doublet Chemotherapy ◽

Platinum Doublet

Download Full-text

Atezolizumab in Japanese Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Subgroup Analysis of the Phase 3 OAK Study

Clinical Lung Cancer ◽

10.1016/j.cllc.2018.01.004 ◽

2018 ◽

Vol 19 (4) ◽

pp. e405-e415 ◽

Author(s):

Toyoaki Hida ◽

Reiko Kaji ◽

Miyako Satouchi ◽

Norihiko Ikeda ◽

Atsushi Horiike ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Subgroup Analysis ◽

Japanese Patients ◽

Small Cell Lung ◽

Phase 3 ◽

Previously Treated

Download Full-text

Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): Results from the confirmatory phase 3 ASCEND-5 study

Annals of Oncology ◽

10.1093/annonc/mdw435.41 ◽

2016 ◽

Vol 27 ◽

pp. vi579 ◽

Author(s):

G. Scagliotti ◽

T.M. Kim ◽

L. Crinò ◽

G. Liu ◽

C. Gridelli ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Small Cell Lung ◽

Phase 3 ◽

Anaplastic Lymphoma ◽

Previously Treated ◽

Confirmatory Phase

Download Full-text

Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70452-8 ◽

2014 ◽

Vol 15 (12) ◽

pp. 1369-1378 ◽

Author(s):

Suresh S Ramalingam ◽

Pasi A Jänne ◽

Tony Mok ◽

Kenneth O'Byrne ◽

Michael J Boyer ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Advanced Stage ◽

Small Cell Lung ◽

Phase 3 ◽

Double Blind ◽

Previously Treated

Download Full-text

MO01.32 CodeBreaK 200: A Phase 3 Multicenter Study of Sotorasib, a KRAS(G12C) Inhibitor, versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS p.G12C Mutation

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2020.10.137 ◽

2021 ◽

Vol 16 (1) ◽

pp. S29

Author(s):

M. Reck ◽

A. Spira ◽

B. Besse ◽

J. Wolf ◽

F. Skoulidis ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Multicenter Study ◽

Small Cell Lung ◽

Phase 3 ◽

Previously Treated

Download Full-text